SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
U.S. Physical Therapy, Inc. (USPH) trades at a trailing P/E of 75.9, forward P/E of 26.8. Trailing earnings yield is 1.32%, forward earnings yield 3.73%. PEG 0.26 (Peter Lynch undervalued ≤1.0). Graham Number is $34.05.
Criteria proven by this page:
- VALUE (36/100, Fail) — trailing P/E is well above the S&P 500 average of ~25, suggesting a premium valuation (P/E 75.9).
- Forward P/E 26.8 (down from trailing 75.9) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.26 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 1.32% — below bond yields — investors are paying a premium for expected growth rather than current earnings. Forward yield improves to 3.73% as earnings recover.
- Analyst consensus target $102.00 (+32.2% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 59/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✗
VALUE
36/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — USPH
Valuation Multiples
P/E (TTM)75.9
Forward P/E26.8
PEG Ratio0.26
Forward PEG0.26
P/B Ratio2.46
P/S Ratio1.71
EV/EBITDA14.2
Per Share Data
EPS (TTM)$1.02
Forward EPS (Est.)$2.88
Book Value / Share$50.75
Revenue / Share$45.04
FCF / Share$4.02
Yields & Fair Value
Earnings Yield1.32%
Forward Earnings Yield3.73%
Dividend Yield2.35%
Graham Number$34.05
SharesGrow IV$50.65 (-34.3%)
Analyst Target$102.00 (+32.2%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2016 |
42.7 |
-5.81 |
4.68 |
2.46 |
0.97% |
| 2017 |
40.8 |
5.57 |
4.43 |
2.19 |
1.11% |
| 2018 |
128.3 |
-2.35 |
6.00 |
2.86 |
0.90% |
| 2019 |
51.8 |
0.11 |
6.07 |
3.03 |
1.00% |
| 2020 |
50.5 |
-5.67 |
5.59 |
3.65 |
0.27% |
| 2021 |
44.3 |
4.53 |
4.17 |
2.49 |
1.52% |
| 2022 |
37.2 |
-1.45 |
3.33 |
1.90 |
2.03% |
| 2023 |
90.1 |
-1.46 |
2.78 |
2.18 |
1.83% |
| 2024 |
50.5 |
1.15 |
2.73 |
1.99 |
1.99% |
| 2025 |
78.7 |
-3.45 |
2.49 |
1.52 |
2.31% |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$1.64 |
$356.55M |
$20.55M |
5.8% |
| 2017 |
$1.76 |
$414.05M |
$22.26M |
5.4% |
| 2018 |
$0.80 |
$453.91M |
$10.1M |
2.2% |
| 2019 |
$4.49 |
$481.97M |
$57.26M |
11.9% |
| 2020 |
$4.09 |
$422.97M |
$52.49M |
12.4% |
| 2021 |
$4.49 |
$495.02M |
$57.92M |
11.7% |
| 2022 |
$3.34 |
$553.14M |
$43.41M |
7.8% |
| 2023 |
$1.28 |
$604.8M |
$14.67M |
2.4% |
| 2024 |
$1.67 |
$560.55M |
$26.46M |
4.7% |
| 2025 |
$1.42 |
$780.99M |
$15.06M |
1.9% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$2.88 |
$2.26 – $3.35 |
$838.76M |
$826.52M – $855.89M |
5 |
| 2027 |
$3.31 |
$2.70 – $3.83 |
$885.12M |
$860.3M – $906.5M |
5 |
| 2028 |
$3.88 |
$3.78 – $4.02 |
$984.55M |
$965.4M – $1.01B |
1 |
